Isolation of therapeutic antibodies against Pseudomonas aeruginosa

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to isolate and produce therapeutic monoclonal antibodies targeting Pseudomonas aeruginosa, a pathogenic bacterium known for its multi-antibiotic resistance, particularly in hospital settings. By focusing on patients with existing functional anti-Pseudomonas antibodies, the study seeks to develop an alternative treatment option for infections caused by antibiotic-resistant strains. The approach involves collecting blood samples from eligible patients at Grenoble University Hospital to identify and isolate these antibodies for potential therapeutic use.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patient selected in the retrospective part of the study (patient with serum containing functional anti-Pseudomonas aeruginosa antibodies)
* Patient with weight ≥ 32kg.
* With a follow-up visit at Grenoble University Hospital with a blood sampling for its care
* Having given its written no objection to participate in the prospective phase of this project

Exclusion Criteria:

* Legally protected patient (minor, pregnant or nursing woman, ward or ward curated, hospitalized under duress or deprived of liberty)

Where it's running

• Chu Grenoble Alpes
  Grenoble, France Recruiting

Study contacts

• Principal investigator: Yvan CASPAR, Dr — University Hospital, Grenoble
• Study coordinator: Yvan CASPAR, Dr
• Email: ycaspar@chu-grenoble.fr
• Phone: +33 4 76 76 54 79

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Single antibiotic versus two antibiotics for Pseudomonas bone infection

  This study will test whether one antibiotic works as well as two for adults with bone infections caused by Pseudomonas aeruginosa.

  Recruiting Centre Hospitalier de Saint-Denis · Saint-Denis, France · NCT07056881

• Investigating gut bacteria in critically ill patients

  This study looks at how a specific gut bacteria called Pseudomonas aeruginosa affects critically ill surgical patients to see if it plays a role in their health and survival.

  Recruiting University of Chicago · Hyde Park, Illinois · NCT06822465

• Assessing treatments for difficult-to-treat Pseudomonas infections

  This study is testing different antibiotic treatments for tough Pseudomonas infections to see which ones work best for patients needing intravenous therapy.

  Recruiting at 4 sites Centre Hospitalier Régional d'Orléans · Amiens and 47 other locations · NCT06738771

• Using fecal microbiota transplantation to eliminate drug-resistant bacteria from the gut

  This study is testing whether a treatment called fecal microbiota transplantation can help people get rid of tough drug-resistant bacteria in their gut.

  Recruiting Phase 1/2 Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Roma · NCT05791396

• Using fecal microbiota transplantation to treat antibiotic-resistant infections

  This study is testing whether a treatment using healthy gut bacteria from donors can help people get rid of hard-to-treat infections caused by antibiotic-resistant germs.

  Recruiting Phase 1/2 Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Rome · NCT04759001

• AZD0292 for bronchiectasis with chronic Pseudomonas colonization

  This Phase 2 study tests whether AZD0292 given by IV can reduce exacerbations in Chinese adults with bronchiectasis who are chronically colonized with Pseudomonas aeruginosa.

  Recruiting at 40 sites Phase 2 AstraZeneca · Anyang and 39 other locations · NCT07774403

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.